BBIO (BridgeBio Pharma) Price-to-Tangible-Book : (As of Jul. 12, 2025)

View and export this data going back to 2019. Start your Free Trial

What is BridgeBio Pharma Price-to-Tangible-Book?

As of today (2025-07-12), BridgeBio Pharma's share price is $46.47. BridgeBio Pharma's Tangible Book per Share of Mar. 2025 for the quarter that ended in Mar. 2025 was $-8.83. Hence, BridgeBio Pharma's Price to Tangible Book Ratio of today is .

The historical rank and industry rank for BridgeBio Pharma's Price-to-Tangible-Book or its related term are showing as below:

During the past 8 years, BridgeBio Pharma's highest Price to Tangible Book Ratio was 150.98. The lowest was 5.48. And the median was 12.81.

BBIO's Price-to-Tangible-Book is not ranked ^*
in the Biotechnology industry.
Industry Median: 3.03
* Ranked among companies with meaningful Price-to-Tangible-Book only.

A closely related ratio is called PB Ratio. As of today, BridgeBio Pharma's share price is $46.47. BridgeBio Pharma's Book Value per Sharefor the quarter that ended in Mar. 2025 was $-8.68. Hence, BridgeBio Pharma's P/B Ratio of today is .

BridgeBio Pharma Price-to-Tangible-Book Historical Data

The historical data trend for BridgeBio Pharma's Price-to-Tangible-Book can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BridgeBio Pharma Price-to-Tangible-Book Chart

BridgeBio Pharma Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Price-to-Tangible-Book

Get a 7-Day Free Trial

150.98

BridgeBio Pharma Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Price-to-Tangible-Book	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of BridgeBio Pharma's Price-to-Tangible-Book

For the Biotechnology subindustry, BridgeBio Pharma's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BridgeBio Pharma's Price-to-Tangible-Book Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BridgeBio Pharma's Price-to-Tangible-Book distribution charts can be found below:

* The bar in red indicates where BridgeBio Pharma's Price-to-Tangible-Book falls into.

Save Embed

;

Save Embed

;

BridgeBio Pharma Price-to-Tangible-Book Calculation

BridgeBio Pharma's price-to-tangible-book ratio for today is calculated as:

Price to Tangible Book	=	Share Price	/	Tangible Book per Share (Q: Mar. 2025 )
	=	46.47	/	-8.83
	=

It can also be calculated from the numbers for the whole company:

Price to Tangible Book	=	Market Cap	/	Tangible Equity
	=	Market Cap	/	(Total Stockholders Equity	-	Preferred Stock	-	Intangible Assets)

A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.

Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.

BridgeBio Pharma Price-to-Tangible-Book Related Terms

Thank you for viewing the detailed overview of BridgeBio Pharma's Price-to-Tangible-Book provided by GuruFocus.com. Please click on the following links to see related term pages.

BridgeBio Pharma Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BridgeBio Pharma Inc (NAS:BBIO) » Definitions » Price-to-Tangible-Book

Comparable Companies

Traded in Other Exchanges

1BBIO:Italy 2CL:Germany

Address

3160 Porter Drive, Suite 250, Palo Alto, CA, USA, 94304

Website

https://www.bridgebio.com

BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis) , is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.

Executives

Neil Kumar	director, officer: See Remarks	C/O BRIDGEBIO PHARMA, INC., 3160 PORTER DR, STE 250, PALO ALTO CA 94304
Kkr Genetic Disorder L.p.	10 percent owner	C/O KOHLBERG KRAVIS ROBERTS & CO. L.P., 9 WEST 57TH STREET, SUITE 4200, NEW YORK NY 10019
Andrew Lo	director	C/O ALPHASIMPLEX GROUP, LLC, ONE CAMBRIDGE CENTER, 9TH FLOOR, CAMBRIDGE MA 02142
Andrea Ellis	director	C/O BRIDGEBIO PHARMA, INC., 421 KIPLING STREET, PALO ALTO CA 94301
Hannah Valantine	director	1305 O'BRIEN DRIVE, MENLO PARK CA 94025
Brian C Stephenson	officer: See Remarks	3160 PORTER DR, STE 250, PALO ALTO CA 94304
Viking Global Investors Lp	10 percent owner	600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
Randal W Scott	director	171 MAIN STREET #225, LOS ALTOS CA 94022
Frank Mccormick	officer: Chairman of Oncology	C/O UCSF, 1450 3RD STREET, RM HD-371, SAN FRANCISCO CA 941439001
Viking Global Opportunities Parent Gp Llc	10 percent owner	600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
Douglas A. Dachille	director	175 WATER STREET, NEW YORK NY 10038
Ronald J Daniels	director	C/O MOORE CORPORATION LIMITED, ONE CANTERBURY GREEN, STAMFORD CT 06901
Fred Hassan	director	C/O CARET GROUP,, 1100 HOLLAND DR., BOCA RATON FL 33487
James C Momtazee	director	2884 SAND HILL ROAD, SUITE 100, MENLO PARK CA 94025
Brent L Saunders	director	2000 GALLOPING HILL ROAD, C/O SCHERING PLOUGH CORP, KENILWORTH NJ 07033